Format

Send to

Choose Destination
PLoS One. 2014 May 9;9(5):e97366. doi: 10.1371/journal.pone.0097366. eCollection 2014.

Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants.

Author information

1
The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; School of Immunity and Infection, MRC Centre for Immune Regulation, University of Birmingham Edgbaston, Birmingham, United Kingdom.
2
Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
3
Department of Infectious Disease and Tropical Medicine, Heartlands Hospital, Birmingham, United Kingdom.
4
Department of Respiratory Medicine, The Friarage Hospital, Northallerton, United Kingdom.
5
The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
6
School of Immunity and Infection, MRC Centre for Immune Regulation, University of Birmingham Edgbaston, Birmingham, United Kingdom.
7
Royal Centre for Defence Medicine (Academia and Research), Joint Medical Command, Birmingham, United Kingdom.

Abstract

BACKGROUND:

Identifying latent tuberculosis infection (LTBI) in people migrating from TB endemic regions to low incidence countries is an important control measure. However, no prospective longitudinal comparisons between diagnostic tests used in such migrant populations are available.

OBJECTIVES:

To compare commercial interferon (IFN)-gamma release assays (IGRAs) and the tuberculin skin test (TST) for diagnosing LTBI in a migrant population, and the influence of antecedent TST and LTBI treatment on IGRA performance.

MATERIALS AND METHODS:

This cohort study, performed from February to September 2012, assessed longitudinal IGRA and TST responses in Nepalese military recruits recently arrived in the UK. Concomitant T-SPOT.TB, QFT-GIT and TST were performed on day 0, with IGRAs repeated 7 and 200 days later, following treatment for LTBI if necessary.

RESULTS:

166 Nepalese recruits were prospectively assessed. At entry, 21 individuals were positive by T-SPOT.TB and 8 individuals by QFT-GIT. There was substantial agreement between TST and T-SPOT.TB positives at baseline (71.4% agreement; κ = 0.62; 95% CI:0.44-0.79), but only moderate concordance between positive IGRAs (38.1% agreement; κ = 0.46; 95% CI:0.25-0.67). When reassessed 7 days following TST, numbers of IGRA-positive individuals changed from 8 to 23 for QFT-GIT (p = 0.0074) and from 21 to 23 for T-SPOT.TB (p = 0.87). This resulted in an increase in IGRA concordance to substantial (64.3% agreement; κ = 0.73; 95% CI:0.58-0.88). Thus, in total on day 0 and day 7 after testing, 29 out of 166 participants (17.5%) provided a positive IGRA and of these 13 were TST negative. Two hundred days after the study commenced and three months after treatment for LTBI was completed by those who were given chemoprophylaxis, 23 and 21 participants were positive by T-SPOT.TB or QFT-GIT respectively. When individual responses were examined longitudinally within this population 35% of the day 7 QFT-GIT-positive, and 19% T-SPOT.TB-positive individuals, were negative by IGRA. When the change in the levels of secreted IFN-γ was examined after chemoprophylaxis the median levels were found to have fallen dramatically by 77.3% from a pre-treatment median concentration of IFN-γ 2.73 IU/ml to a post-treatment median concentration IFN-γ 0.62 (p = 0.0002).

CONCLUSIONS:

This study suggests differences in the capacity of commercially available IGRAs to identify LTBI in the absence of antecedent TST and that IGRAs, in the time periods examined, may not be the optimal tests to determine the success of chemoprophylaxis for LTBI.

PMID:
24816576
PMCID:
PMC4016319
DOI:
10.1371/journal.pone.0097366
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center